On November 28, 2022 Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, reported the acceptance of two poster presentations evaluating the potential use and utility of its novel RPPA (Reverse Phase Protein Array) technology at the San Antonio Breast Cancer Symposium (SABCS) 2022 (Press release, Theralink Technologies, DEC 1, 2022, View Source [SID1234624733]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mick Ruxin M.D., CEO of Theralink Technologies stated, "We are so pleased to have multiple poster presentations accepted at SABCS this year. During our presentations we will highlight the potential of our innovative RPPA-based technology for clinical molecular profiling of breast cancer patients. With the excitement around advancements in treatment options for patients with HER2 Low metastatic breast cancer, it is important as ever to have clarity on HER2 status. The Theralink Assay for Advanced Breast Cancer can provide additional levels of quantified clarity for patients who need it the most."
Additional details on the upcoming posters and corresponding abstracts are shown below. Full text of the abstracts are available on the SABCS website here.
Spotlight Poster Presentation:
Title: ‘Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 INC 0 "Ultra Low" Setting: Implications for Precision Therapy in HER2- Breast Cancer.’
Session Title: HER2 Low: A Sperate Entity? Special Session – Hall 3
Date: Wednesday, December 7, 2022
Time: 9:45 – 11:00 am CT
Poster Presentation:
Title: ‘Impact of the Theralink CLIA Protein/Phosphoprotein Assay on Treatment Selection in Routine Clinical Practice: a Prospective Observational Study in Advance Breast Cancer.’
Program Number: P4-07-51
Session Title: Poster Session #4 – Hall 1
Date: Thursday, December 8, 2022
Time: 7:00 – 8:15 am CT
The Theralink management team welcomes the opportunity to meet with you in-person in San Antonio at SABCS 2022. Please email [email protected] if you would like to arrange for a private meeting with Theralink representatives.